BioVaxys Technology Corp. (TSE:BIOV) is facing a management cease trade order (MCTO) from the British Columbia Securities Commission (BCSC) due to a delay in filing its audited annual financial statements and related documents.
The delay stems from BioVaxys’ recent acquisition of intellectual property and clinical-stage assets from IMV Inc., which has extended the audit process. While the MCTO restricts trading by the company’s CEO and CFO, the general public can still trade the company’s shares.
BioVaxys is committed to providing alternative information and anticipates completing the required filings by March 30, 2025.
About BioVaxys Technology Corp.
BioVaxys Technology Corp. is a clinical-stage biopharmaceutical company headquartered in British Columbia, Canada. The company focuses on developing innovative immunotherapies using its proprietary DPX™ immune-educating technology platform and HapTenix© ‘neoantigen’ tumor cell construct platform. These platforms are designed to treat cancers, infectious diseases, and other immunological conditions.
BioVaxys is actively advancing its clinical-stage pipeline. Key programs include maveropepimut-S, currently in Phase II clinical development for advanced Relapsed-Refractory Diffuse Large B Cell Lymphoma and platinum-resistant ovarian cancer. The company is also preparing for Phase I trials in Spain for BVX-0918, a personalized immunotherapeutic vaccine to treat late-stage ovarian cancer.
